Related Experiment Videos
Intravenous immunoglobulin prophylaxis in neonates on artificial ventilation
M Adhikari1, A G Wesley, P B Fourie
1Department of Paediatrics and Child Health, University of Natal, Durban.
Summary
Prophylactic intravenous immunoglobulin (Ig) did not significantly reduce infections or improve outcomes in ventilated neonates. A trend towards fewer infections was observed in term infants, suggesting potential benefits from newer immunotherapies.
Area of Science:
- Neonatal Medicine
- Immunology
- Clinical Trials
Background:
- Neonatal sepsis is a significant cause of morbidity and mortality.
- Intravenous immunoglobulin (Ig) is used to augment passive immunity.
- Prophylactic Ig efficacy in ventilated neonates requires further evaluation.
Purpose of the Study:
- To evaluate the prophylactic efficacy of intravenous immunoglobulin (Ig) in ventilated neonates.
- To assess the impact of Ig on infection rates, ventilation duration, and clinical recovery.
- To identify potential benefits in specific neonatal subgroups.
Main Methods:
- Double-blind, placebo-controlled trial involving 21 pairs of ventilated neonates.
- Infants received either 0.4 g/kg/day of intravenous Ig or placebo for 5 days.
- Efficacy assessed by infection frequency, ventilation duration, and time to recovery.
Main Results:
- No significant differences in positive blood/endotracheal cultures or abnormal white cell counts between groups.
- Significantly higher IgG levels in the treated group by day 6 (P < 0.05).
- Similar clinical improvement, ventilation duration, antibiotic treatments, and mortality rates between groups.
Conclusions:
- Prophylactic intravenous Ig offers no significant benefit for ventilated neonates.
- A trend suggested fewer infections in term infants treated with Ig.
- Future research should explore hyperimmune gammaglobulin or monoclonal antibodies for neonatal sepsis.